The Best Biotech CEO of 2012 Is...

BOSTON ( TheStreet) -- The best biotech CEO of 2012 is Leonard Schleifer of Regeneron Pharmaceuticals ( REGN).

Schleifer was the top pick of TheStreet readers for his execution of one of the most successful new drug launches in history. Eylea was approved in November 2011 to treat a common cause of blindness. In just nine months, Eylea sales have already reached $562 million with an annual run rate close to $1 billion, well above the company's -- and investors' -- initial forecasts.

Well done, Len!

Schleifer wins the 2012 Best Biotech CEO Award with 37% of 1,121 votes cast. For his victory, Schleifer takes home the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO.

The runner-up this year was Onyx Pharmaceuticals' ( ONXX) Tony Coles with 28% of votes cast. With two new cancer drug approvals in 2012, Coles had a stellar year.

Right behind Coles in third place, just six votes short, was Chris Garabedian of Sarepta Therapeutics ( SRPT). In fourth place: Gilead Sciences' ( GILD) John Martin.

Congratulation to all of this year's Best Biotech CEO nominees, and thanks to everyone who participated in the voting process.

-- Reported by Adam Feuerstein in Boston.

More from Stocks

Sears Finally Files for Chapter 11 Bankruptcy

Sears Finally Files for Chapter 11 Bankruptcy

From Catalogs to Catastrophe: A Sears Timeline

From Catalogs to Catastrophe: A Sears Timeline

What Happens to Sears Gift Cards and Warranties Now That Chain Is Bankrupt?

What Happens to Sears Gift Cards and Warranties Now That Chain Is Bankrupt?

Nvidia 'Is Going to Miss the Quarter,' Jim Cramer Says

Nvidia 'Is Going to Miss the Quarter,' Jim Cramer Says

Ring Up Some Income With This Under-the-Radar Dividend Stock

Ring Up Some Income With This Under-the-Radar Dividend Stock